Drugs / PF-06763809
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03469336 | Apr 2018 → Mar 2019 | psoriasis | Pfizer | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06763809 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03469336 ↗ |
| Action | Inhibit | “The RORC2 inhibitor PF-06763809 has been hypothesized to inhibit IL-17A production in T-helper 17 (Th17) cells, thereby reducing psoriasis symptoms.” PMID 32767679 ↗ Sep 2020 |
| Route | Topical | “Participants received each of the following six treatments once daily for 18 days: three topical doses (2.3%, 0.8%, 0.23%) of PF-06763809, a vehicle and two active comparators...” PMID 32767679 ↗ Sep 2020 |
| Target | RORC | “The RORC2 inhibitor PF-06763809 has been hypothesized to inhibit IL-17A production in T-helper 17 (Th17) cells, thereby reducing psoriasis symptoms.” PMID 32767679 ↗ Sep 2020 |